Respiratory mucosal vaccination of peptide-poloxamine-DNA nanoparticles provides complete protection against lethal SARS-CoV-2 challenge

Si Sun,Entao Li,Gan Zhao,Jie Tang,Qianfei Zuo,Larry Cai,Chuanfei Xu,Cheng Sui,Yangxue Ou,Chang Liu,Haibo Li,Yuan Ding,Chao Li,Dongshui Lu,Weijun Zhang,Ping Luo,Ping Cheng,Yuwei Gao,Changchun Tu,Bruno Pitard,Joseph Rosenecker,Bin Wang,Yan Liu,Quanming Zou,Shan Guan

DOI: https://doi.org/10.1016/j.biomaterials.2022.121907

IF: 14

Biomaterials

Abstract:The ongoing SARS-CoV-2 pandemic represents a brutal reminder of the continual threat of mucosal infectious diseases. Mucosal immunity may provide robust protection at the predominant sites of SARS-CoV-2 infection. However, it remains unclear whether respiratory mucosal administration of DNA vaccines could confer protective immune responses against SARS-CoV-2 challenge due to insurmountable barriers posed by the airway. Here, we applied self-assembled peptide-poloxamine nanoparticles with mucus-penetrating properties for pulmonary inoculation of a COVID-19 DNA vaccine (pSpike/PP-sNp). The pSpike/PP-sNp not only displays superior gene transfection and favorable biocompatibility in the mouse airway, but also promotes a tripartite immunity consisting of systemic, cellular, and mucosal immune responses that are characterized by mucosal IgA secretion, high levels of neutralizing antibodies, and resident memory phenotype T-cell responses in the lungs of mice. Most importantly, immunization with pSpike/PP-sNp completely eliminates SARS-CoV-2 infection in both upper and lower respiratory tracts and enables 100% survival rate of mice following lethal SARS-CoV-2 challenge. Our findings indicate PP-sNp is a promising platform in mediating DNA vaccines to elicit all-around mucosal immunity against SARS-CoV-2.